- Conditions
- COPD
- Interventions
- Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Ventolin 90Mcg/Actuation Inhalation Aerosol
- Drug
- Lead sponsor
- Pulmonary Research Institute of Southeast Michigan
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Farmington Hills, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Copd
- Interventions
- TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Asthma
- Interventions
- Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Trelegy Ellipta, Stiolto Respimat, Furoate/Umeclidinium/Vilanterol, Tiotropium Bromide/Olodaterol
- Device · Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 11,316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Eden Prairie, Minnesota
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists, Fluticasone furoate/umeclidinium/vilanterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah
- Conditions
- Asthma
- Interventions
- FF/UMEC/VI, ELLIPTA, FF/VI
- Drug · Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 23 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
- Device · Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 9,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- White Plains, New York